Stay updated on Safety Efficacy of Rituximab & Pembrolizumab in Waldenström's Clinical Trial
Sign up to get notified when there's something new on the Safety Efficacy of Rituximab & Pembrolizumab in Waldenström's Clinical Trial page.

Latest updates to the Safety Efficacy of Rituximab & Pembrolizumab in Waldenström's Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe webpage has undergone significant changes, including the removal of detailed information about a Phase II trial for treating Waldenström Macroglobulinemia, while adding new references to trial identifiers and collaborators.SummaryDifference35%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check88 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Safety Efficacy of Rituximab & Pembrolizumab in Waldenström's Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety Efficacy of Rituximab & Pembrolizumab in Waldenström's Clinical Trial page.